FHTX compared with GENB: revenue, margins and what each company keeps, and the suppliers and customers both name

FHTXFoghorn Therapeutics Inc.

Mkt capRevenueRevenue

GENBGenerate Biomedicines, Inc.

Mkt capRevenueRevenue

Compare

FHTXFoghorn Therapeutics Inc.

GENBGenerate Biomedicines, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FHTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±84.1%▲+14.14%×0.17

May 7 '26±62.5%▼−10.26%×0.16

Q1 FY26±13.9%▼−12.92%×0.93

Jan 12 '26±84.2%▲+23.64%×0.28

GENB1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.14%—

= impliedFHTX realized, solidGENB realized, hatchedOne scale, both sides: full bar = 85%× = |realized| ÷ impliedSource: market data

FHTXFoghorn Therapeutics Inc.

2.08· pre 2.08· delayed

Mkt cap$123.5MRevenue$16MQ2 FY26Revenue$31MFY25

GENBGenerate Biomedicines, Inc.

14.49· pre 14.52

Pre-marketSep 2 '83

Mkt cap$1.9BRevenue$6MQ2 FY26Revenue—

Compare

Pre-marketSep 2 '83

FHTXFoghorn Therapeutics Inc.

GENBGenerate Biomedicines, Inc.

2.08pre 2.08delayed

Price

14.49pre 14.52

$123.5M

Mkt cap

$1.9B

Q2 FY26$16M

Revenue

$6MQ2 FY26

FY25$31M

Revenue

—

FHTX2.08vsGENB14.49Pre-marketSep 2 '83